Home » Stocks » Assertio Therapeutics

Assertio Therapeutics, Inc. (ASRT)

Stock Price: $0.672 USD -0.040 (-5.64%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $0.675 +0.003 (0.45%) Oct 21, 5:33 PM

Stock Price Chart

Key Info

Market Cap 71.99M
Revenue (ttm) 155.91M
Net Income (ttm) -182.56M
Shares Out 107.12M
EPS (ttm) -2.19
PE Ratio n/a
Forward PE 5.48
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $0.672
Previous Close $0.712
Change ($) -0.040
Change (%) -5.64%
Day's Open 0.716
Day's Range 0.663 - 0.716
Day's Volume 434,548
52-Week Range 0.550 - 1.710

More Stats

Market Cap 71.99M
Enterprise Value 111.79M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 107.12M
Float 92.06M
EPS (basic) -2.43
EPS (diluted) -2.19
FCF / Share -0.04
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.08M
Short Ratio 2.12
Short % of Float 1.17%
Beta 2.02
PE Ratio n/a
Forward PE 5.48
P/FCF Ratio n/a
PS Ratio 0.46
PB Ratio 0.90
Revenue 155.91M
Operating Income -243.50M
Net Income -182.56M
Free Cash Flow -4.26M
Net Cash -39.81M
Net Cash / Share -0.37
Gross Margin 141.10%
Operating Margin -156.18%
Profit Margin -117.10%
FCF Margin -2.73%
ROA -4.28%
ROE -129.29%
ROIC -109.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(269.05% upside)
Current: $0.672
Target: 2.48
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-26.39%-18.11%-16.49%33.02%-12.2%190.87%47.78%-31.7%64.64%-
Gross Profit22029330836827537512784.7812772.67
Operating Income-19443.66-42.1824.51-50.402379.32-30.3570.703.63
Net Income-21736.91-102-88.72-75.7413243.31-29.7870.733.90
Shares Outstanding70.7263.7962.7061.3060.1258.2956.7455.8954.5652.53
Earnings Per Share-3.070.57-1.63-1.45-
EPS Growth-----173.33%--1700%-
Operating Cash Flow90.4872.5062.1771.26152-55.929.75-30.9957.65-2.38
Capital Expenditures-1.48-5.36-0.39-2.86-1.72-0.60-1.81-6.88-0.70-0.18
Free Cash Flow88.9967.1461.7868.40151-56.527.94-37.8756.95-2.56
Cash & Equivalents42.1111112817721055927266.8186.1570.35
Total Debt351566627719800230---2.17
Net Cash / Debt-309-455-499-541-59133027266.8186.1568.18
Book Value57.9622017025131536413783.9410623.11
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Assertio Therapeutics, Inc.
Country United States
Employees 125
CEO Todd N. Smith

Stock Information

Ticker Symbol ASRT
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ASRT
IPO Date November 5, 1997


Assertio Holdings operates as a specialty pharmaceutical company in the United States. Its specialty pharmaceutical products include CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for treating migraine; Zipsor, an NSAID for relief of mild to moderate acute pain; Gralise, a once-daily formulation of gabapentin for the management of postherpetic neuralgia; NUCYNTA ER, an extended-release version of tapentadol for the management of neuropathic pain associated with diabetic peripheral neuropathy; and NUCYNTA IR, an immediate release version of tapentadol for the management of moderate to severe acute pain. The company has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.